Podcasts about UPMC

Joshua Levenson MD is an Assistant Professor of Medicine at the University of Pittsburgh School of Medicine. He studied Chemistry at Amherst College followed by medicine at the University of Pittsburgh and internal medicine residency at The University of Michigan. He returned to the University of Pittsburgh Medical Center for Cardiology Fellowship prior to joining faculty in 2017. Dr Levenson is a noninvasive cardiologist, cardiac imager, and clinician educator. He serves as Director of UPMC's Center for Cardio-Oncology, co-Director of Noninvasive at UPMC Shadyside, and Associate Director of UPMC's Cardiology Fellowship.

Dr. Rob Bart is the Chief Medical Information Officer at UPMC, where he is leading one of the largest EHR consolidations in the country- bringing the entire health system onto a single Epic instance. A pediatric intensivist by training, Rob has been a pioneer in the CMIO role for more than two decades, with prior leadership at Cerner and Los Angeles County Department of Health Services. In this episode of DGTL Voices, Rob tells Ed about growing up in Hawaii (his high school classmate happened to become President of the United States), the conversation that pulled him from research into medicine, why clinicians need to keep practicing to keep their credibility, and his case against the endless creation of new C-suite titles every time technology evolves. Plus: the trust framework he uses with his team, why recovering from a wrong decision matters more than being right the first time, and how bike rides through a cemetery near his home keep him grounded.

If your marketing feels like a lot of effort… with inconsistent results—this episode is for you.In this conversation with Dave Masovich, we break down the real reason most marketing doesn't convert—and it's not because you're not posting enough.It's because you're missing the strategy behind the message.Inside this episode, we cover:✨ The difference between tactical vs. strategic marketing (and why most business owners focus on the wrong one) ✨ Why 40–60% of marketing efforts are wasted—and how to stop the leak ✨ The power of the 80/20 rule (Pareto Principle) in your marketing strategy ✨ The six key places to uncover insights that shape a powerful, resonant message ✨ Why message clarity—not more content—is the real driver of growth ✨ How to create marketing that actually connects, converts, and builds long-term trustIf you've been feeling stuck, plateaued, or like your marketing “should be working better than it is”… this episode will shift how you think—and how you show up.Our Guest Info:Dave Mastovich is the CEO and Founder of MASSolutions, a growth marketingconsultancy reinventing the way marketing is done. He helps organizations drive growth inrevenue, talent, and engagement by improving how they sell, communicate, market, and aligntheir people.Dave is the author of No Bullsh!t Marketing, a #1 Best Seller, and host of the long-running NoBullsh!t Marketing Show. His approach turns data, behavior, and patterns into practical actionsleaders can use to drive real performance.Earlier in his career at UPMC, Dave's marketing leadership helped drive growth from under $1billion to $10 billion. Today he brings that same mix of cognitive science, 80/20 analysis, andreal-world execution to help organizations grow sales, strengthen culture, and increaseenterprise value.https://davemastovich.com/https://massolutions.biz/https://www.linkedin.com/in/davidmmastovich/Your GO-TO LINK for all things Visibility-: Google Business Profile Optimization, The Website + Social Media Audit, The Visibility Blueprint, Newsletter, & Referral Partners.Love today's podcast?

What is precision medicine, and how should precision medicine be handled in the face of guidelines and protocols? In this episode of the Society of Critical Care Medicine (SCCM) Podcast, Diane C. McLaughlin, DNP, AGACNP-BC, CCRN, FCCM, speaks with Michael R. Pinsky, MD, FAPS, MCCM, about his Thought Leader presentation at the 2026 Critical Care Congress, The Effective Management of Shock: Moving From Physiology to Guidelines to Precision Medicine and Ultimately Personalized Medicine. The panel also discusses how to titrate care for individual patients. Protocols and guidelines are the foundation for patient care and are instrumental for having all healthcare professionals on the same baseline when treating patients. Precision medicine involves individualizing care for a specific patient, and Dr. Pinsky emphasizes that guidelines should never supersede an understanding of pathophysiology at the bedside, including observing your patient and paying attention to how individual patients respond to specific treatments. Monitoring the individualized response is required for the best care. Michael R. Pinsky, MD, FAPS, MCCM, is a professor of critical care medicine, bioengineering, and anesthesiology at the University of Pittsburgh in Pittsburgh, Pennsylvania, USA. He is also Docteur Honoris Casusa at the Université René Descartes Paris V School of Medicine in Paris, France. In 2012, he became one of the first 20 critical care physicians to receive a Master of Critical Care Medicine (MCCM) from SCCM. He is currently an emeritus (honorary) at UPMC. At the University of Pittsburgh, he is vice-chair emeritus for the Department of Critical Care Medicine and a faculty member at the Center for Critical Care Nephrology and the Center for Military Medicine Research. Resources referenced in this podcast: The Effective Management of Shock: Moving From Physiology to Guidelines to Personalized Medicine

Soul Pitt Media Health & Business Report Episode #115 | Interview with Diane Powell | Director, Community And Family BuildersJoin Craig as he discusses with Diane...1) Ms. Powell, can you talk to our listeners about Community and Family Builders?2) Can you talk to our listeners about the impact of dementia on women in the African American Community?3) How important is early detection?Additionally, make sure you listen to our Community Calendar (brought to you by Pittsburgh Regional Transit, PRT) with Debbie Norrell at the end of each of our interviews so you can keep up with what's going on in our Pittsburgh region.Soul Pitt Media's Health & Business Report is sponsored by UPMC, Pittsburgh Regional Transit (PRT), Duquesne Light Co., Allegheny County Health Department, Pennsylvania's Children's Health Insurance Program (CHIP), and Central Outreach Wellness Center.

In this episode, Atizazul Mansoor, MD, Chair of the Heart and Vascular Institute at UPMC in Central Pennsylvania, and Samir Saba, MD, Professor of Medicine and Chief of Cardiology at the UPMC Heart and Vascular Institute, join the podcast to discuss how their organization is restructuring to better meet the growing demands in cardiology. They share perspectives on reducing the length of education and training pathways to encourage more physicians to enter the field and help address workforce needs.

In this episode, Brendan Harris, President, UPMC for You and State Programs & Patti Jackson-Gehris, President, UPMC North Central and Williamsport markets, discuss UPMC's strategies to improve rural healthcare access through workforce development, telehealth expansion, and innovative care models that address geographic and socioeconomic barriers.

In this episode, Brendan Harris, President, UPMC for You and State Programs & Patti Jackson-Gehris, President, UPMC North Central and Williamsport markets, discuss UPMC's strategies to improve rural healthcare access through workforce development, telehealth expansion, and innovative care models that address geographic and socioeconomic barriers.

Soul Pitt Media Health & Business Report Episode #114 | Interview with Leslie Howze and Yazmin Bennett Kelly from Project ButterflyJoin Craig as he discusses with Leslie and Yazim...1) Leslie, can you talk to our listeners about Project Butterfly?2) Yazmin, who can qualify for Project Butterfly?3) Leslie, when I read information preparing for this podcast I was shocked to learn of the great differences in infant mortality between Black and White infants. What can that be attributed to?Additionally, make sure you listen to our Community Calendar (brought to you by Pittsburgh Regional Transit, PRT) with Debbie Norrell at the end of each of our interviews so you can keep up with what's going on in our Pittsburgh region.Soul Pitt Media's Health & Business Report is sponsored by UPMC, Pittsburgh Regional Transit (PRT), Duquesne Light Co., Allegheny County Health Department, Pennsylvania's Children's Health Insurance Program (CHIP), and Central Outreach Wellness Center.

On this episode of CEOs You Should Know, we spotlight two inspiring leaders making a real impact in the fight against cancer—Ann Regan and Beth Wild. Their conversation centers around the upcoming Rush to Crush Cancer Weekend, happening May 16–17, and the powerful mission behind it.From community-driven fundraising to groundbreaking research at the UPMC Hillman Cancer Center, this episode dives into how every mile ridden and every dollar raised is helping accelerate progress toward a world without cancer. Ann shares how the event has grown into a regional movement, while Beth offers insight into how those funds directly impact patient care and innovation.Whether you're a cyclist, a survivor, or someone looking to make a difference, this conversation is a reminder that together, we can turn hope into action—and action into results.https://www.rushtocrushcancer.org/

In this episode, Dan is joined by Erin Angelini to dive into soft tissue injuries and mgmt. of soft tissue injuries in field sport athletes. Erin Angelini is a Doctor of Physical Therapy and Head of Rehab for the Orlando Pride, working at the intersection of sports medicine and performance in elite women's soccer. Residency-trained at UPMC, she holds her Sports Certified Specialist (SCS) and sports science certification, bringing a systems-based approach to return-to-play, load management, and soft tissue injury prevention. Erin specializes in bridging the gap between rehab and performance to keep athletes available at the highest level.Connect with Erin: https://www.linkedin.com/in/erin-angeliniSeason 7 of the Braun Performance & Rehab Podcast is proudly supported by Pura Health, bringing ultrasound into every clinician's hands. Learn more at purahealth.net and @pura.health_ultrasound.Additional support provided by Firefly Recovery, the official recovery partner of Braun Performance & Rehab (recoveryfirefly.com), and Dr. Ray Gorman of Engage Movement. Learn how to grow your income beyond sessions—follow @raygormandpt on Instagram and DM “Dan” for a free breakdown of the blended practice model.Episode Affiliates: Airbands BFR (Coupon Code: DANIELBRAUN for 10% off), MoboBoard (BRAWNBODY10), AliRx (DBraunRx), MedBridge (BRAWN)If you enjoyed this episode, share it with someone who would benefit and leave a 5-star review.Explore more from Dan at linktr.ee/braun_pr.

Yinz Are Good shares the good stuff, the good news, going on out there and celebrates the good people who are making it happen: The people who are lifting others up, who are taking care of their neighbors... the people who unite us by building community.We're thrilled to let yinz know that several countries have recently joined our list of who's listening in, bringing our total to…89 countries and territories on 6 continents. Wow! It's an absolute joy to have you all here. And, as our numbers continue to grow, what stands out most is that this community of ours actually has nothing to do with borders or nationalities, and has everything to do with the fact that generosity, kindness, compassion, and celebrating community all feel the same, no matter where we live or what language we speak. They are, quite simply, human. And they are what unites us.And you're gonna hear all about these “uniters” in this episode, and also about giving back and saying thank you. All courtesy of The Twilight Wish Foundation. Their mission is to honor and enrich the lives of seniors through intergenerational wish celebrations. There are chapters all over the U.S., including one right here in Southwest Pennsylvania and Tressa had the delight of sitting down with Missy Counahan, the Director of the Pittsburgh area chapter. As you'll learn, Missy is a helper to her core and has dedicated her life to helping our older friends, neighbors, and family members. This episode is filled with stories of compassion, love and kindness. Twilight Wish (Allegheny County/Pittsburgh): https://twilightwish.org/chapter-locations/allegheny-county-pennsylvania/Twilight Wish - main website: https://twilightwish.org/UPMC's Living-At-Home Program: https://www.upmc.com/services/seniors/living-at-home/contactWatch our Tressa Tries…video series on YouTube⁠ here⁠.⁠⁠https://www.yinzaregood.com/⁠⁠⁠⁠⁠FOLLOW US on social media:Instagram:⁠⁠⁠ ⁠@yinzaregood⁠⁠⁠⁠ Facebook:⁠⁠⁠ ⁠@YinzAreGood⁠⁠⁠⁠Have a story of generosity or kindness to share with us? Want a Kindness Crate dropped off at your business or school? Email us at ⁠yinzaregood@gmail.com.

Soul Pitt Media Health & Business Report Episode #113 | Interview with Gabrielle Haywood, Playwright/ProducerJoin Craig as he discusses with Gabrielle...1) Gabrielle, growing up were you always interested in the arts?2) Gabrielle, you currently have a play debuting, can you talk to our listeners about your play?3) How can you purchase tickets for your play?Additionally, make sure you listen to our Community Calendar (brought to you by Pittsburgh Regional Transit, PRT) with Debbie Norrell at the end of each of our interviews so you can keep up with what's going on in our Pittsburgh region.Soul Pitt Media's Health & Business Report is sponsored by UPMC, Pittsburgh Regional Transit (PRT), Duquesne Light Co., Allegheny County Health Department, Pennsylvania's Children's Health Insurance Program (CHIP), and Central Outreach Wellness Center.

Dr. Jenna Skowronski, Dr. Shazli Khan, and Dr. Alix Barnes discuss the involvement of palliative care throughout the heart failure spectrum with Dr. Sarah Chuzi. Audio editing for this episode was performed by CardioNerds Intern, Dr. Julia Marques Fernandes. In this episode, we discuss utilizing palliative care principles while caring for patients with heart failure, particularly those being considered for advanced therapies. We emphasize utilization of communication frameworks when discussing prognosis and making decisions on pursuing therapies such as palliative inotropes, left ventricular assist devices (LVADs), and heart transplant. Additionally, we discuss when to involve specialty palliative care services. Finally, we highlight the difference between palliative care and hospice and how to help patients navigate the transition from life-prolonging care to hospice. Dr. Jenna Skowronski is the Chair for the CardioNerds Heart Failure Council. Dr. Jenna Skowronski and Dr. Shazli Khan are the Co-chairs for the CardioNerds Advanced Heart Failure Therapies Series. Dr. Alix Barnes is the CardioNerds FIT Ambassador at UPMC and member of the CardioNerds Critical Care Cardiology Council. Enjoy this Circulation Paths to Discovery article to learn more about the CardioNerds mission and journey. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscripts here. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Primary palliative care is care provided by a clinician that is not a palliative care specialist, such as a heart failure clinician having a conversation with a patient about their goals and values in clinic.  Taking time to get to know a patient as an individual and learning their goals and values prior to diving into conversations about prognosis and change in treatment plan facilitates more effective goals of care discussions.   Utilizing and practicing a communication framework can improve our skills at goals of care discussions.   Palliative inotropes should be reserved for patients experiencing symptomatic benefit from the therapy that outweighs the associated risks including arrhythmias and infections. The burden of managing these therapies at home should also be considered. Partnerships between cardiologists and hospice agencies can improve the experience for patients with heart failure who enroll in hospice. Cardiologists can continue to see their patients even after hospice enrollment and help with symptom management.   Notes Notes: Notes drafted by Dr. Barnes. 1. What is the difference between primary palliative care and specialty palliative care? Primary palliative care is the delivery of palliative care services that any clinician can deliver. This includes aligning treatment with a patient's goals and basic symptom management. For heart failure patients, symptom management can include cardiac symptoms such as dyspnea and chest pain as well as managing comorbid mood disorders such as adjustment disorder, depression, and anxiety. Advanced palliative care skills take additional training and time to develop. These include leading a difficult family meeting, managing symptoms that are not controlled with standard therapies and responding to emotional and spiritual distress. When these situations are encountered, referral to a specialty palliative care service should be considered. 1 2. How is palliative care integrated throughout the disease trajectory of a patient with heart failure? Heart failure clinicians deliver primary palliative care when assessing a patient's preferences, goals and values or managing symptoms. As a patient's disease progresses, the heart failure team also engages in primary palliative care when delivering news about prognosis. When advanced therapies are being considered, utilization of shared decision-making (SDM) should be employed (see question 3 for further discussion on SDM). For patients being considered for LVAD, the Centers for Medicare and Medicaid Services (CMS) mandates that patients are seen by a palliative care specialist prior to implantation. 2 Despite this, there remains variability in how institutions involve specialty palliative care in this decision-making process. Thoughtful consideration of what palliative care resources are available at your institution should guide how best to integrate specialty palliative care teams into the LVAD decision tree. One example of a model for meeting this mandate is having a small team of heart failure clinicians with additional palliative care training meet all patient's being evaluate for LVAD. 3. What is shared decision-making (SDM) and how is it utilized when evaluating a patient for advanced therapies? SDM is a collaborative process where patients and clinicians work together to make medical decisions that are aligned with a patient's goals and values.3 There are a variety of communication frameworks that can be used to engage in effective SDM. One framework is the Serious Illness Conversation guide. This is an evidenced based framework that can be used to deliver the news about a patient's current condition and then assess their goals, values and preferences for next steps in their treatment plan.4  This framework can be helpful when discussing prognosis prior to introducing the idea of an evaluation for advanced therapies. REMAP is a second commonly used framework which stands for Reframe, Expect Emotion, Map What's Important, Align, and Plan.5 This framework is similarly helpful when starting a discussion about advanced therapies with a patient. Both frameworks prioritize learning about a patient's goals, values, and preferences prior to making a recommendation for a treatment plan. Listening more than speaking and accepting that a patient and their family may choose a path that is different than what you personally might choose for yourself or your loved ones are vital pillars to engaging in these conversations effectively. When discussing LVAD, it is important to avoid framing the decision as “LVAD or no LVAD,” rather LVAD versus best supportive care. The “Best Case, Worst Case” framework is an effective way to create choice awareness for patients when they are faced with making this decision. This is a way to discuss both the best outcomes after LVAD implantation as well as the potential complications so a patient is better able to understand the full spectrum of possible outcomes. 6 4. How do you select which patients would benefit from home inotrope therapy? There is no data demonstrating a survival benefit with use of palliative inotropes. There may be subsets of patients who derive a survival benefit, such as patients whose renal function worsens when the agent is withdrawn, however there is no concrete data proving this. 7 Therefore, the benefit of home inotrope therapy should be based on if the patient derives symptomatic benefit from these agents. Additionally, risks of the therapy such as arrhythmias and infection as well as the burden of managing these therapies at home should also be weighed in the decision.8 Life expectancy for patients being initiated on palliative inotropes likely ranges from 6 to 9 months. Given this prognosis, concordant palliative care efforts should be intensified when starting patients on these agents. This can either be through involvement in specialty palliative care or increasing primary palliative care interventions. 9 5. How do you determine if a patient would be a candidate for hospice and how do you discuss hospice with patients and their families? Hospice is a comprehensive program that provides supportive care to patients at end of life. This includes a team of physicians, nurses, aids, social workers and chaplains that can deliver care in the home, at a nursing facility, or in an inpatient hospice facility. 10 Patients with a prognosis of 6 months or less can qualify for hospice services. Even if a patient qualifies for hospice based on their prognosis, it is important to assess if a patient's goals and values align with hospice. Introducing hospice to patients who still desire life prolonging care can cause mistrust between the patient and their health care team. When introducing hospice, it is helpful to describe the services hospice offers in addition to naming the service as some patients may have a negative connotation with the word “hospice.” 6. How can cardiologists partner with hospice agencies to provide better care for these patients? Heart failure specialists can continue to see their patients even after they enroll in hospice. Partnering in hospice agencies in this way can help improve symptom management for patients while also allowing them to continue meaningful relationships with providers with whom they've developed a longitudinal relationship with. Guideline directed medical therapy (GDMT) and diuretics can be continued while enrolled in hospice as long as they are offering symptomatic benefit. Heart failure specialists can help with adjusting GDMT to cheaper formulations, such as exchanging angiotensin receptor-neprilysin inhibitors (ANRIs) for angiotensin receptor blockers (ARBs). Many hospice agencies cannot accept patients receiving palliative inotropes due to the resources and training required to safely care for these patients. Understanding what hospice agencies in your area can and cannot support allows heart failure specialists to have informed discussions with patients and make appropriate referrals. References Quill TE, Abernethy AP. Generalist plus Specialist Palliative Care — Creating a More Sustainable Model. N Engl J Med. 2013;368(13):1173-1175. doi:10.1056/NEJMp1215620. https://www.nejm.org/doi/full/10.1056/NEJMp1215620 Ventricular Assist Devices for Bridge-to-Transplant and Destination Therapy. Published online August 1, 2013. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=268 Godfrey S, Barnes A, Gao J, Katz JN, Chuzi S. Shared Decision-making in Palliative and End‑of‑life Care in the Cardiac Intensive Care Unit. US Cardiol Rev. 2024;18:e13. doi:10.15420/usc.2024.03. https://pubmed.ncbi.nlm.nih.gov/39494405/ Baxter R, Pusa S, Andersson S, Fromme EK, Paladino J, Sandgren A. Core elements of serious illness conversations: an integrative systematic review. BMJ Support Palliat Care. 2024;14(e3):e2268-e2279. doi:10.1136/spcare-2023-004163. https://pmc.ncbi.nlm.nih.gov/articles/PMC11671901/ Childers JW, Back AL, Tulsky JA, Arnold RM. REMAP: A Framework for Goals of Care Conversations. J Oncol Pract. 2017;13(10):e844-e850. doi:10.1200/JOP.2016.018796. https://ascopubs.org/doi/10.1200/JOP.2016.018796 Kruser JM, Nabozny MJ, Steffens NM, et al. “Best Case/Worst Case”: Qualitative Evaluation of a Novel Communication Tool for Difficult in-the-Moment Surgical Decisions. J Am Geriatr Soc. 2015;63(9):1805-1811. doi:10.1111/jgs.13615. https://pmc.ncbi.nlm.nih.gov/articles/PMC4747100/ Tolia S, Khan M, Khan S, et al. Mortality and long-term outcomes of palliative inotropes in ischemic and non-ischemic cardiomyopathy. Eur Heart J.  2021;42(Supplement_1):ehab724.0915. doi:10.1093/eurheartj/ehab724.0915. https://academic.oup.com/eurheartj/article/42/Supplement_1/ehab724.0915/6392681 Chuzi S, Allen LA, Dunlay SM, Warraich HJ. Palliative Inotrope Therapy: A Narrative Review. JAMA Cardiol. 2019;4(8):815. doi:10.1001/jamacardio.2019.2081. https://jamanetwork.com/journals/jamacardiology/article-abstract/2737414#google_vignette Chuzi S, Gao J, Thariath J, et al. Characteristics and Outcomes of Palliative Continuous Intravenous Inotrope Support Among Medicare Beneficiaries With Heart Failure. J Am Heart Assoc. 2025;14(14):e039397. doi:10.1161/JAHA.124.039397. https://www.ahajournals.org/doi/10.1161/JAHA.124.039397 What is hospice? Published online September 24, 2024. https://hospicefoundation.org/what-is-hospice/

It's Trans Day of Visibility! We're sharing some events and ways to mark the day in Pittsburgh, plus looking at where trans youth are going for gender-affirming care now that UPMC ended these services for patients under 19.  We're also discussing the latest population numbers, a new platform to rate local landlords, the newest PA "bird town," and a new outdoor music festival. Thanks to Hanna Webster, health reporter for the Post-Gazette, for discussing her reporting on gender-affirming care. Don't forget to tell us what you love about Pittsburgh to be entered into our $1,000 giveaway! And we're also inviting you 412 Day, a totally real holiday to celebrate what makes Pittsburgh, Pittsburgh.  Notes and references from today's show: Population Change in the Pittsburgh Region [University Center for Social and Urban Research] Pittsburgh area loses population amid nationwide immigration crackdown [Post-Gazette] PODCAST: Pittsburgh Isn't Growing. Is That Actually Bad? [City Cast Pittsburgh] PODCAST: UPMC Didn't Challenge Trump, So These Pittsburgh Families Did [City Cast Pittsburgh] Trans teens in Pittsburgh scramble to access care months after options were largely cut off [Post-Gazette] ‘Knowledge is power:' Rate Yinz Landlord offers students a voice on Oakland landlords [The Pitt News] Richland Township named Pennsylvania's 100th Bird Town [TribLive] Live osprey camera back on at Moraine State Park [Butler Eagle] First baby eagle of 2026 hatches at U.S. Steel Irvin Plant nest [WTAE] Pittsburgh eagle cam captures chilling coyote howls: "Never heard anything like this" [KDKA] New Pittsburgh music festival launches this summer in Frick Park [WESA] Learn more about the sponsors of this March 31st episode: Pittsburgh Cultural Trust Quantum Theatre Allegheny County Poll Workers Become a member of City Cast Pittsburgh at membership.citycast.fm. Want more Pittsburgh news?  Sign up for our daily morning newsletter. We're on Instagram @CityCastPgh. Text or leave us a voicemail at 412-212-8893. Interested in advertising with City Cast? Find more info here.

Michael is joined by Steelers Vice President of Business Development and Strategy Dan Rooney, Steelers legend Will Allen and American Football Ireland President Alan Lomasney as the Steelers touched down in Dublin last week for the inaugural Steelers Flag Football Tournament, presented by Aer Lingus and UPMC.See omnystudio.com/listener for privacy information.

Dr. Donald Yealy (Chief Medical officer UPMC) joins the show to discuss the Flu and the Flu Shots impact

A federal judge just issued a scathing ruling saying the Department of Justice can't force UPMC Children's Hospital to hand over young patients' medical records. The DOJ had demanded information about minors who were receiving gender-affirming care. "There is more than a whiff of ill-intent," Chief Judge Cathy Bissoon wrote. "Arguably, it is closer to a stench." But the legal battle isn't over, and UPMC has stopped providing most forms of gender-affirming care for young people. Mimi McKenzie, legal director at the Public Interest Law Center, joins executive producer Mallory Falk to explain how she came to represent four local patients and their families, why she found it "hugely disappointing" that UPMC didn't bring its own legal challenge against the government, and what's happening with similar cases across the country. Learn more about the sponsors of this March 16th episode: P3R The Westmoreland Carnegie Library Become a member of City Cast Pittsburgh at membership.citycast.fm. Want more Pittsburgh news?  Sign up for our daily morning newsletter. We're on Instagram @CityCastPgh. Text or leave us a voicemail at 412-212-8893. Interested in advertising with City Cast? Find more info here.

Third-party risk is no longer a background concern for healthcare organizations -- it is a frontline challenge. Jason Kor, Principal at HITRUST, works on the company's third-party risk management team, helping enterprises understand the security risk embedded in their supply chains. The numbers tell a stark story: according to Security Scorecard, 99% of the world's 2,000 largest companies are actively connected to a vendor that has experienced a breach in the past 18 months. And Verizon's Data Breach Investigations Report shows that the share of breaches tied to a third party has doubled year over year. HITRUST exists precisely to help organizations move from awareness to action. HITRUST will be at HIMSS 2026 in Las Vegas, March 9-12, at Booth 11307. Stop playing whack-a-mole with vendor risk -- step into the VR challenge and win prizes. For organizations already holding a HITRUST certification, the team has something else waiting: a trophy recognizing the commitment to independent, external audits and rigorous security standards. For those exploring certification for the first time, the booth is a chance to understand how HITRUST compares to alternatives like SOC 2 questionnaires -- and why scalability and risk reduction make it the stronger choice for supply chain assurance. Kor puts it plainly: the audits are time-consuming and expensive because they are effective. And at the end of the process, someone reads that report and makes real business decisions based on what it contains. Two major themes converge at this year's event: supply chain risk and AI. HITRUST has already launched an AI security assessment offering, and new CSF releases are on the horizon, including a report center feature enabling online review of assessments for anti-fraud and continuous monitoring purposes. On Tuesday, March 10, 2026, from 11:10 AM to 11:30 AM, Kor will deliver a 20-minute session titled "Understanding AI Security Risk -- The New Blind Spot in TPRM and Supply Chain Resilience." The session addresses a rapidly evolving challenge: as organizations build their own generative AI tooling -- or work with third parties that have integrated AI into their products -- questions around data sovereignty, input handling, and model provenance become critical, especially in healthcare where electronic health information is at stake. Also on the HIMSS 2026 agenda from HITRUST: Ryan Patrick, Executive Vice President of TPRM Customer Solutions, joins John P. Houston of UPMC and Chuck Christian of Franciscan Health for a Brunch Briefing titled "Building Secure, Compliant, and Resilient Healthcare Systems Together" on Tuesday, March 10, 2026, from 10:30 AM to 11:45 AM at Level 1, Casanova 505. The session offers practical strategies, frameworks, and real-world lessons for organizations looking to reduce risk, enhance protection, and advance trust in an evolving threat and regulatory landscape. This is a Brand Spotlight. A Brand Spotlight is a ~15 minute conversation designed to explore the guest, their company, and what makes their approach unique. Learn more: https://www.studioc60.com/creation#spotlight GUEST Jason Kor, Principal, HITRUSThttps://www.linkedin.com/in/securityconsultantcissp/ RESOURCES HITRUST: https://hitrustalliance.net Jason Kor Session -- Understanding AI Security Risk -- The New Blind Spot in TPRM and Supply Chain Resilience (Tuesday, March 10, 2026, 11:10 AM - 11:30 AM): https://app.himssconference.com/event/himss-2026/planning/UGxhbm5pbmdfNDMyMTMxOA== Building Secure, Compliant, and Resilient Healthcare Systems Together -- Brunch Briefing (Tuesday, March 10, 2026, 10:30 AM - 11:45 AM): https://app.himssconference.com/event/himss-2026/planning/UGxhbm5pbmdfNDMzNzQwMQ== HIMSS 2026 Global Health Conference and Exhibition: https://www.itspmagazine.com/cybersecurity-technology-society-events/himss-global-health-conference-amp-exhibition-2026 Are you interested in telling your story? ▶︎ Full Length Brand Story: https://www.studioc60.com/content-creation#full ▶︎ Brand Spotlight Story: https://www.studioc60.com/content-creation#spotlight ▶︎ Brand Highlight Story: https://www.studioc60.com/content-creation#highlight KEYWORDS Jason Kor, HITRUST, Sean Martin, brand story, brand marketing, marketing podcast, brand spotlight, third-party risk management, TPRM, supply chain risk, healthcare cybersecurity, HIMSS 2026, AI security, generative AI risk, HITRUST CSF, cybersecurity certification, data sovereignty, electronic health information, vendor risk management Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Back pain is one of the most common causes of reduced mobility and loss of independence as we age. In this episode, spine surgeon Dr. Gbolahan Okubadejo explains the causes of back and neck pain, when conservative treatment is appropriate, and when spine surgery may become the best option for restoring mobility and quality of life. Chronic back and neck often trigger fear. Many people assume pain is inevitable, that surgery always leads to long downtime, or that recovery means permanent limitation. In this episode, we explore modern advances in spine care, recovery, and how the right mindset and preparation can help people reclaim movement, confidence, and independence at any age. Dr. Gbolahan Okubadejo is a board-certified, fellowship-trained spinal and orthopedic surgeon and founder of the Institute for Comprehensive Spine Care, with offices across New York and New Jersey. A graduate of Brown University and Johns Hopkins University School of Medicine, he completed his orthopedic residency at Washington University in St. Louis and a spine fellowship at UPMC. He is also the creator of the 360 Dynamized Core system for spine-safe core strengthening.    Episode Timeline: 00:00 — A personal story: emergency spine surgery and recovery   05:40 — Why spine pain becomes more common with age   09:10 — Imaging vs symptoms: understanding the disconnect   12:55 — How surgeons decide who needs surgery    18:20 — Mindset, movement, and recovery outcomes    22:10 — Minimally invasive and endoscopic techniques     26:40 — Core strength, prevention, and daily habits      32:50 — A practical action for people in pain today   Connect with Dr. Gbolahan Okubadejo  www.nynjspine.com 360coreboard.com Call to Action:   Find "Growing Older Living Younger: The Science of Aging Gracefully and the Art of Retiring Comfortably" (North America only) or on Kindle. Subscribe to Growing Older Living Younger on your favorite podcast platform and leave a review to help others discover the show.  Join the Growing Older Living Younger Community  Connect with Dr. Gillian Lockitch   email: askdrgill@gmail.com

Dr. Pedro Barata and Dr. Kathryn Schmitz discuss evidence-based exercise oncology programs, how to incorporate exercise into cancer care and connect the right patient to the right program, and ultimately build a culture of exercise in oncology. TRANSCRIPT Dr. Pedro Barata: Hello, and welcome to By the Book, a podcast series from ASCO that features compelling perspectives from authors and editors of the ASCO Educational Book. I'm Dr. Pedro Barata. I'm a medical oncologist and a clinical trialist at the University Hospital Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also happy to serve as a deputy editor for the ASCO Educational Book. Today, we'll be talking about exercise. We have plenty of evidence that exercise benefits symptoms, improves the quality of life of patients, and actually has been shown to reduce risk of recurrence of cancer but also improve survival. And I think that's increasingly clear as data emerges. Today, I'm delighted to be speaking to Dr. Kathryn Schmitz. She's a leading expert on integrating exercise into cancer care. Dr. Schmitz serves as the deputy director of the University of Pittsburgh Hillman Cancer Center and also a professor of hematology-oncology at University of Pittsburgh Medical School. She's the senior author of a fantastic article in the ASCO Educational Book that's titled "Implementation Science as the Secret Sauce for Integrating Exercise Screening and Triage Pathways in Oncology." She also led a really compelling piece that just got published in JCO titled "If Exercise Were a Pill, We'd All Prescribe It to Patients With Cancer. But It's Not" So I'm thrilled to have Dr. Schmitz joining us today and helping us explore evidence-based exercise oncology programs, how to incorporate exercise into cancer care, and also how to connect the right patient to the right program.  So with that, welcome, Dr. Schmitz. Thank you so much for taking the time to chat with us. Dr. Kathryn Schmitz: Thank you for the opportunity. Dr. Pedro Barata: One of the highlights of ASCO last year and practice changing, in my opinion, data out of The New England [Journal of Medicine] is called the CHALLENGE trial. It did provide high level evidence that a structured, supervised exercise program could improve both disease-free survival and overall survival. This is a study in the GI world, but I think it got a lot of attraction and attention beyond the GI world, across solid tumors, really. Could you give us a little brief recap of that trial and what have you seen as being the impact in practices around oncology? Dr. Kathryn Schmitz: So, CHALLENGE was very exciting. Prior to CHALLENGE, there were any number of observational studies that indicated that there was a relationship between being more physically active and reduced recurrence and improved overall survival for colon cancer in particular. You know, notably, in 2006, Jeff Meyerhardt published two papers in the same journal, of the same issue of JCO, showing very, very similar data from two very large studies. And those were studies number five and six in this area. You know, there's a lot of evidence observationally, but we don't generally change clinical practice on the basis of observational data. So, we were all waiting very impatiently for the results of the CHALLENGE trial. And it was very exciting to be in the front row when the results were reported out and to be part of the group with a standing ovation for the authors when it was presented. To summarize, 889 colon cancer patients, stage II and III, were randomized into either a structured exercise program or a health education control comparison group and followed for an average of 7.9 years. And the structured exercise group had a 27% reduced risk of recurrence and a 38% improvement in overall survival. One of the things that's really notable about this is that what we typically expect is that when we go from the observational literature to the clinical trial literature, that we expect effects to go down. We expect to see a larger effect in the observational than in the RCT land, and that did not happen here. We actually see an effect that matches what we've seen in observational literature, which is really, really exciting.  And, you know, one of the reasons why this has been so exciting across not just GI but other cancers is the notable finding of a reduced risk of second primaries. So, they only observed two breast cancer second primaries in the treatment group and 12 in the comparison group. And overall, they reduced the second primaries occurrence, hazard ratio was 0.5, a 50% reduction of second primaries, which is just remarkable. It really got everybody very, very excited. And now the big question, of course, is, all right, how do I do this? How do I make this happen?  The thing to note is that what they did in CHALLENGE is probably not doable in your clinic tomorrow. It's a heavy intervention. The number of touchpoints from staff is extensive, and the amount of time needed from staff for the coaching and supervised exercise is extensive as well. The criteria for getting people into the program required that people go through a series of blood tests and imaging tests that would just simply not be possible for the average community oncologist. So I'm guessing that you're going to ask me some questions about how we do this. Dr. Pedro Barata: Right. That's a fantastic segue. That's exactly right. Walk us through maybe starting by, what does that mean? Dr. Kathryn Schmitz: The first thing to say is I have to go back to the observational literature. And the observational literature shows really compellingly that we have a strong reduction of breast cancer recurrence and mortality from being more physically active, prostate cancer recurrence and mortality, and colon cancer recurrence and mortality. I find it very difficult to believe in this day and age, in our current environment, if you will, that we are ever going to have the equivalent of CHALLENGE for prostate or for breast cancer. There is an ongoing study in prostate that's led by some Australian researchers, but I just don't think that it's likely that we're going to mount something similar for another tumor site. We have tremendous correlative data that indicates that there are a number of biomarkers and biological pathways through which breast, colon, and prostate cancer would be reduced in recurrence if people were more physically active. And so, there is really, from my thinking, very little to state that it would be just a colon cancer effect. And so this is something we probably can enact in more than just the colon cancer community, overall, which is great news, and it makes it easier for us to be able to enact this type of programming. Dr. Pedro Barata: One of the things that comes up perhaps often is, if I were the leader of the cancer center and were to incentivize the different care teams to implement an exercise program at each level: GI team, GU, breast, thoracic, etc. How do we do that? Dr. Kathryn Schmitz: So, I want to give you an analogy. You're a medical oncologist, and you prescribe your patients chemotherapy. Now, just imagine, if you will, what would happen and how likely it would be for your patients to get chemotherapy if there was no chemoinfusion suite. If the chemoinfusion suite disappeared tomorrow and you were to tell your patients, "Go get some chemotherapy," what proportion of those patients do you think would go find all of the equipment necessary and all of the drugs necessary and understand how to dose the chemotherapy for themselves and get that all done? Very few people would do it. So with exercise, why would we be surprised then that our patients don't actually do a whole lot if we just simply tell them to go get some exercise? Exercise is a medicine. It is effective like a medicine. We've shown this through the CHALLENGE trial and many other correlative studies and an ocean of observational data as well. So the question is, how do we build the infrastructure that is necessary in order for your patients to do this? So the very first thing that has to happen is that somebody has to tell the patient to exercise. We currently do not have a culture of exercise in oncology. We do in heart disease. If you ask the average person on the street, "Is exercise good for your heart?" Anybody with an eighth-grade education is going to say, "Yes, of course," because the American Heart Association has done an amazing job telling everybody that exercise is good for your heart. But what has ASCO done, frankly? Can I be that bold? What has ASCO done to tell patients that they should be exercising during and after their cancer treatment? I'm not sure that I know more than a guideline. There is a guideline, and that's great. And the guideline is very helpful, but I'm not sure that patients know that there's a guideline. In fact, I can tell you that patients don't know that there is a guideline. So, you know, making sure that there's a paradigm shift in the country that says exercise is good for patients during and after their cancer treatment is the first step. The second step is getting a medical professional to say something to the patient about the exercise. And I'm very careful with the two words that I just chose: medical professional. I do understand medical oncologists are very busy. I understand that there's a whole lot to say in that 15 minutes when you're with the patient. And so maybe it isn't the medical oncologist. Ideally, it would be, but I get it that there's limited time. So it could be a nurse practitioner, it could be a nurse, there could be a social worker, it could be somebody else on the team that says, "Hey, you know, we want you to do an exercise program. We want to connect you to an exercise program." And then there's what is the program itself? You know, I'm very interested in this happening across the entire country. And so I've been working with the leadership of the Commission on Cancer on the question of, well, how would you do this in community oncology? You know, it's not enough to do it in academic medicine, but how do you do this in community oncology? And you can't expect that every community hospital is going to build a gym for their cancer patients. That is just not reasonable to do. So, we start to try to figure out some phone counseling. Could we give people Fitbits and follow them? Could we use technology to help us? Are there telehealth opportunities for us to do? Are there apps that have been built? In fact, there is a [free] app called Cancer Exercise that's on, you know, all of the platforms and available to patients. So there are programs. I've developed a directory of over 2,000 programs that exist across the country for exercise oncology that patients can find, medical oncologists can find.  So there are a lot of people trying to figure out how best to get the information to medical oncologists and other medical professionals so that they can have an 'easy button' to be able to connect their patients to existing programming so that you don't feel like you have to build a whole new program. Dr. Pedro Barata: If I don't have the resources around me, what would be your advice for the care team or for the providers that might not have that available at their site? Where do they start? Who do they reach out to? Who should they be looking at to get more information on how to set it up? Dr. Kathryn Schmitz: I lead an international consortium called Moving Through Cancer. You can find us at movingthroughcancer.org. That's where you'll find the map of all of the programs across the country and the directory. We actually have a triage tool that sits at the front of the directory that allows people to discern what type of exercise they're safe to do. We do recognize that, you know, the 80-year-old that fell last week doesn't need the same program as the 35-year-old that was playing pickleball the day before diagnosis. So, you know, there are different kinds of programs for people at different levels of acuity. We're happy to be helpful to folks to help them set up programs.  But the number one thing is to really be very aware of the power of saying something about doing exercise, just simply the power of saying, "I want you to be moving." Because frankly, I don't think anybody listening to this would disagree, no one benefits from sitting on the couch all day, no one. No one, no one. It doesn't matter how acute their medical issues are. We get people out of bed. We try to move people even when they're in the hospital. So I think saying something is huge. And then, if you can, applying a triage tool, if you can get something embedded within your clinical flow so that you can understand who it is that needs to go to physical therapy as opposed to who's ready for an exercise program. Those are the two things. So triage and referral is kind of step one. And if you can get that done, the rest will fall into place. Dr. Pedro Barata: This is really powerful message, where one, awareness of the care teams. Number two, bring it up to the patient. And then working on the referral, triage and referral process. That's fantastic. Another aspect that comes up quite a bit is like, "Look, this is great, but we have a system that relies on payers to make things happen, or at least to get them approved." And that can be very different or heterogeneous. The coverage can be different. Sometimes already going through a system programs for interventions, therapeutic interventions, let alone probably the insurance is not going to cover that. Is that true? Is it not true? How do you walk through the different insurance supports, perhaps, depending on where you're practicing? Dr. Kathryn Schmitz: You've just hit on the hot button. I've been working on this issue for about nine years now, trying to figure out using efforts to talk to CMS and see if we can get third party payer coverage going. We were making good progress there, and there was a change of administration and a new focus on "Make America Healthy Again," the MAHA movement. And, you know, CMS is really no longer interested in one-off national coverage determination. They instead, they want to know, "How do we make exercise happen for every American over 65?" And my question is, "Well, wait a minute, cancer patients are not just older patients. There's a lot going on there. They need something special." So I've been working on that. It's been working with accrediting bodies for policy with a little p. Very proud of the work that I've done in collaboration with the National Accreditation Program for Breast Centers, trying to get standards to get exercise referrals for breast patients. And I'm currently holding my breath to see whether the CoC is going to try to make some forward motion in this area as well, crossing all period appendages, waiting for news there. So it's not paid for unless it's done by a physical therapist. And, you know, there's published evidence and I have plenty of evidence from UPMC as well, that people don't really want to go to the physical therapist for this. I'm not saying physical therapists aren't great. Physical therapists are great, and there are people who really need to go to physical therapy, and we try hard to get those patients connected. But for the patients that are ready for something more than physical therapy, we really have an uphill battle to try to figure out what insurers are willing to pay for and what the return on investment is.  One of the challenges with the return on investment is that the timeline, time course for return on investment for American insurers is about one year. And I'll remind you that the time course for return on investment for CHALLENGE was 7.9 years. So we have a mismatch there. So we're trying to figure out if we can produce the evidence to show that there is an improvement in unplanned health care utilization. We have documented that for breast cancer. We're working on it for other cancers. If we can document that it is worthwhile to the insurer to pay for these programs, then I believe that they will pay for them. You know, my conversations are very positive with UPMC, which is a very large insurer and a large health plan. We're slowly working our way towards the middle, where there's a program that they can pay for and a program that is efficacious. That's the puzzle we're trying to solve for right now. Dr. Pedro Barata: This has been wonderful and super helpful. Before we wrap it up, is there anything else you would like to share with our listeners? Dr. Kathryn Schmitz: I want to make sure that your audience is aware that there are a variety of ways that exercise oncology is practiced. The program that most oncologists will be familiar with is LIVESTRONG, which is a program at the YMCA. It's a free program. At one point, there were over 800 locations across the U.S. They have contracted since COVID, probably because of COVID. So they still do exist but imagine, if you will, telling your patients that chemo is only available Tuesdays and Thursdays at 7:00 p.m. It would be difficult for patients to get there and get the chemotherapy. The same thing is true for the LIVESTRONG program. It's a fantastic, fantastic program for people who are able to get there, but that's one option. Another option for patients is there are a variety of online opportunities. I'll call out 2Unstoppable for women's cancers. It's literally the number 2Unstoppable.org. It's a free program available to women with cancer to have live, small group training programs. And they're based in Virginia, but they have programs all over the country. And then finally, I just want to overemphasize the app, the Cancer Exercise app. It's literally called Cancer Exercise in the app store. And that is a super duper easy button, very comprehensive, developed by a nurse scientist, Anna Schwartz. And then there are a variety of books. I wrote a book called Moving Through Cancer. There's a new book out [MyExerciseMedicine for Cancer] by Dr. Rob Newton as well, who's an Australian author. And there are certifications for exercise professionals that folks can look into as well through the American College of Sports Medicine. Dr. Pedro Barata: Dr. Schmitz, this is fantastic. Thank you for sharing those great insights with us. Super, super helpful. Thank you for taking the time. Dr. Kathryn Schmitz: Thank you so much. Dr. Pedro Barata: Thank you to our listeners for your time today. Remember, you'll find links to Dr. Schmitz's fantastic Educational Book as well as the JCO articles in the transcript of this episode. I'll invite all of you to go and read. And we'll also include a link to Dr. Schmitz's book titled Moving Through Cancer: An Exercise and Strength Program for the Fight of Your Life, which empowers patients and caregivers in simple five steps.  So with that, please join us again next month on By the Book for more insights on key advances and innovations that are shaping modern oncology. Thank you very much for your attention. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:           Dr. Pedro Barata    @PBarataMD     Dr. Kathryn Schmitz @fitaftercancer Follow ASCO on social media:           @ASCO on X (formerly Twitter)           ASCO on Bluesky          ASCO on Facebook           ASCO on LinkedIn           Disclosures:        Dr. Pedro Barata:    Stock and Other Ownership Interests: Luminate Medical    Honoraria: UroToday    Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon    Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas    Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck     Dr. Kathryn Schmitz: Patents, Royalties, Other Intellectual Property: Fees from the educational program developed by Dr. Schmitz that is now offered through Klose Training and Consulting.

(00:00:00) First, Penny Lenig‑Zerby, director of the UPMC Shadyside School of Nursing in Harrisburg, and Joye Gingrich, UPMC in Central Pa.’s Chief Nursing Officer, share their personal journeys into nursing and what drives them to train the next generation. They discuss the realities of today’s nursing workforce, the many career paths available to new graduates, and how UPMC supports nurses as they enter the field and continue their education. They also outline practical steps for listeners interested in applying to nursing school at a time when demand for skilled nurses has never been higher. (00:22:22) Then, the conversation shifts to Pennsylvania’s hemp and cannabis landscape through the story of Lazy Moon Ranch and its founder, Ron Boyles. After a debilitating back injury and years of opioid dependence, Ron turned to medical cannabis—an experience that helped him reclaim his health and sparked his advocacy for patient access. Today he leads the Green Bridge Society, connecting patients with certifying doctors across multiple states, and cultivates CBD hemp at Lazy Moon Ranch following the 2018 Hemp Farm Bill. Ron shares what distinguishes hemp from cannabis, how the industry works, and what recent legislation means for growers, consumers, and curious newcomers. Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

In today's episode of the America's Work Force Union Podcast, we go behind the scenes of two major labor victories where workers refused to back down in the face of corporate pressure. Segment 1: USW District 1 & Libbey Glass (0:00 - 15:30) USW District 1 Director Donnie Blatt joins the show to recap the conclusion of a grueling five-month strike at Libbey Glass in Toledo. Blatt details how three separate USW Locals—65T, 59M, and 700T—maintained 24/7 picket lines to protect their craft jurisdictions and seniority rights. We discuss the transition from bankruptcy concessions to a contract that restores wage growth and secures healthcare for the future. Segment 2: UPMC Magee Nursing Victory (15:31 - End) Registered Nurses Adrienne Andrews and Sharece Abee explain how they helped lead a successful organizing campaign at UPMC Magee Women's Hospital in Pittsburgh. Working with SEIU Healthcare PA, these frontline caregivers overcame intense anti-union messaging to win their election. They share updates on the first-contract negotiations that began in January and why safe staffing remains their North Star. For more information on these stories, visit our blog at awf.labortools.com

JCO PO author Dr. Foldi at UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine shares insights into the JCO PO article, "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast." Host Dr. Rafeh Naqash and Dr. Foldi discuss how serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I am your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor at the OU Health Stephenson Cancer Center at the University of Oklahoma. Today, we are thrilled to be joined by Dr. Julia Foldi, Assistant Professor of Medicine in the Division of Hematology-Oncology at University of Pittsburgh School of Medicine and the Magee-Womens Hospital of the UPMC. She is also the lead and corresponding author of the JCO Precision Oncology article entitled "Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients with Metastatic Invasive Lobular Carcinoma of the Breast." At the time of this recording, our guest's disclosures will be linked in the transcript. Julia, welcome to our podcast, and thank you for joining us today. Dr. Julia Foldi: Thank you so much for having me. It is a pleasure. Dr. Rafeh Naqash: Again, your manuscript and project address a few interesting things, so we will start with the basics, since we have a broad audience that comprises trainees, community oncologists, and obviously precision medicine experts as well. So, let us start with invasive lobular breast carcinoma. I have been out of fellowship for several years now, and I do not know much about invasive lobular carcinoma. Could you tell us what it is, what some of the genomic characteristics are, why it is different, and why it is important to have a different way to understand disease biology and track disease status with this type of breast cancer? Dr. Julia Foldi: Yes, thank you for that question. It is really important to frame this study. So, lobular breast cancers, which we shorten to ILC, are the second most common histologic subtype of breast cancer after ductal breast cancers. ILC makes up about 10 to 15 percent of all breast cancers, so it is relatively rare, but in the big scheme of things, because breast cancer is so common, this represents actually over 40,000 new diagnoses a year in the US of lobular breast cancers. What is unique about ILC is it is characterized by loss of an adhesion molecule, E-cadherin. It is encoded by the CDH1 gene. What it does is these tumors tend to form discohesive, single-file patterns and infiltrate into the tumor stroma, as opposed to ductal cancers, which generally form more cohesive masses. As we generally explain to patients, ductal cancers tend to form lumps, while lobular cancers often are not palpable because they infiltrate into the stroma. This creates several challenges, particularly when it comes to imaging. In the diagnostic setting, we know that mammograms and ultrasounds have less sensitivity to detect lobular versus ductal breast cancer. When it comes to the metastatic setting, conventional imaging techniques like CT scans have less sensitivity to detect lobular lesions often. One other unique characteristic of ILC is that these tumors tend to have lower proliferation rates. Because our glucose-based PET scans depend on glucose uptake of proliferating cells, often these tumors also are not avid on conventional FDG-PET scans. It is a challenge for us to monitor these patients as they go through treatment. If you think about the metastatic setting, we start a new treatment, we image people every three to four cycles, about every three months, and we combine the imaging results with clinical assessment and tumor markers to decide if the treatment is working. But if your imaging is not reliable, sometimes even at diagnosis, to really detect these tumors, then really, how are we following these patients? This is really the unique challenge in the metastatic setting in patients with lobular breast cancer: we cannot rely on the imaging to tell if patients are responding to treatment. This is where liquid biopsies are really, really important, and as the field is growing up and we have better and better technologies, lobular breast cancer is going to be a field where they are going to play an important role. Dr. Rafeh Naqash: Thank you for that easy-to-understand background. The second aspect that I would like to have some context on, to help the audience understand why you did what you did, is ctDNA, tumor informed and non-informed. Could you tell us what these subtypes of liquid biopsies are and why you chose a tumor informed assay for your study? Dr. Julia Foldi: Yes, it is really important to understand these differences. As you mentioned, there are two main platforms for liquid biopsy assays, circulating tumor DNA assays. I think what is more commonly used in the metastatic setting are non-tumor informed assays, or agnostic assays. These are generally next-generation sequencing-based assays that a lot of companies offer, like Guardant, Tempus, Caris, and FoundationOne. These do not require tumor tissue; they just require a blood sample, a plasma sample, essentially. The next-generation sequencing is done on cell-free DNA that is extracted from the plasma, and it is looking for any cell-free DNA and essentially, figuring out what part of the cell-free DNA comes from the tumor is done through a bioinformatics approach. Most of these assays are panel tests for cancer-associated mutations that we know either have therapeutic significance or biologic significance. So, the results we receive from these tests generally read out specific mutations in oncogenic genes, or sometimes things like fusions where we have specific targeted drugs. Some of the newer assays can also read out tumor fraction; for example, the newest generation Guardant assay that is methylation-based, they can also quantify tumor fraction. But the disadvantage of the tumor agnostic approach is that it is a little bit less sensitive. Opposed to that, we have our tumor informed tests, and these require tumor tissue. Essentially, the tumor is sequenced; this can either be whole exome or whole genome sequencing. The newer generation assays are now using whole genome sequencing of the tumor tissue, and a personalized, patient-specific panel of alterations is essentially barcoded on that tumor tissue. This can be either structural variants or it can be mutations, but generally, these are not driver mutations, but sort of things that are present in the tumor tissue that tend to stay unchanged over time. For each particular patient, a personalized assay, if you want to call it a fingerprint or barcode, is created, and then that is what then is used to test the plasma sample. Essentially, you are looking for that specific cancer in the blood, that barcode or fingerprint in the blood. Because of this, this is a much more sensitive way of looking for ctDNA, and obviously, this detects only that particular tumor that was sequenced originally. So, it is much more sensitive and specific to that tumor that was sequenced. You can argue for both approaches in different settings. We use them in different settings because they give us different information. The tumor agnostic approach gives us mutations, which can be used to determine what the next best therapy to use is, while the tumor informed assay is more sensitive, but it is not going to give us information on therapeutic targets. However, it is quantified, and we can follow it over time to see how it changes. We think that it is going to tell us how patients respond to treatment because we see our circulating tumor DNA levels rise and fall as the cancer burden increases or decreases. We decided to use the tumor informed approach in this particular study because we were really interested in how to determine if patients are having response to treatment versus if they are going to progress on their treatment, more so than looking for specific mutations. Dr. Rafeh Naqash: When you think about these tumor informed assays and you think about barcoding the mutations on the original tumor that you try to track or follow in subsequent blood samples, plasma samples, in your experience, if you have done it in non-lobular cancers, do you think shedding from the tumor has something to do with what you capture or how much you capture? Dr. Julia Foldi: Absolutely. I think there are multiple factors that go into whether someone has detectable ctDNA or not, and that has to do with the type of cancer, the location, right, where is the metastatic site? This is something that we do not fully understand yet: what are tumors that shed more versus not? There is also clearance of ctDNA, and so how fast that clearance occurs is also something that will affect what you can detect in the blood. ctDNA is very short-lived, only has a half-life of hours, and so you can imagine that if there is little shedding and a lot of excretion, then you are not going to be detecting a lot of it. In general, in the metastatic setting, we see that we can detect ctDNA in a lot of cases, especially when patients are progressing on treatment, because we imagine their tumor burden is higher at that point. Even with the non-tumor informed assays, we detect a lot of ctDNA. Part of this study was to actually assess: what is the proportion of patients where we can have this information? Because if we are only going to be able to detect ctDNA in less than 50 percent of patients, then it is not going to be a useful method to follow them with. Because this field is new and we have not been using a lot of tumor informed assays in the metastatic setting, we did not really know what to expect when we set out to look at this. We did not know what was going to be the baseline detection rate in this patient population, so that was one of the first things that we wanted to answer. Dr. Rafeh Naqash: Excellent. Now going to this manuscript in particular, what was the research question, what was the patient population, and what was the strategy that you used to investigate some of these questions? Dr. Julia Foldi: So, we partnered with Natera, and the reason was that their Signatera tumor-informed assay was the first personalized, tumor-informed, really an MRD assay, minimal residual disease detection assay. It has been around the longest and has been pretty widely used commercially already, even though some of our data is still lacking. but we know that people are using this in the real world. We wanted to gather some real-world data specifically in lobular patients. So, we asked Natera to look at their database of commercial Signatera testing and look for patients with stage 4 lobular breast cancer. The information all comes from the submitting physicians sending in pathologic reports and clinical notes, and so they have that information from the requisitions essentially that are sent in by the ordering physician. We found 66 patients who were on first-line or close to first-line endocrine-based therapies for their metastatic lobular breast cancer and had serial collections of Signatera tests. The way we defined baseline was that the first Signatera had to be sent within three months of starting treatment. So, it is not truly baseline, but again, this is a limitation of looking at real-world data is that you are not always going to get the best time point that you need. We had over 350 samples from those 66 patients, again longitudinal ctDNA samples, and our first question was what is the baseline detection rate using this tumor informed assay? Then, most importantly, what is the concordance between changes in ctDNA and clinical response to treatment? That is defined by essentially radiologic response to treatment. Dr. Rafeh Naqash: Interesting. So, what were some of your observations in terms of ctDNA dynamics, whether baseline levels made a difference, whether subsequent levels at different time points made a difference, or subsequent levels at, let us say, cycle three made a difference? Were there any specific trends that you saw? Dr. Julia Foldi: So, first, at baseline, 95 percent of patients had detectable ctDNA, which is, I think, a really important data point because it tells us that this can be a really useful test. If we can detect it in almost all patients before they start treatment, we are going to be able to follow this longitudinally. And again, these were not true baseline samples. So, I think if we look really at baseline before starting treatment, almost all patients will have detectable ctDNA in the metastatic setting. The second important thing we saw was that disease progression correlated very well with increase in ctDNA. So, in most patients who had disease progression by imaging, we saw increase in ctDNA. Conversely, in most patients who had clinical benefit from their treatment, so they had a response or stable disease, we saw decrease in ctDNA levels. It seems that what we call molecular response based on ctDNA is tracking very nicely along with the radiographic response. So, those were really the two main observations. Again, this is a small cohort, limited by its real-world nature and the time points that ctDNA assay was sent was obviously not mandated. This is a real-world data set, and so we could not really look at specific time points like you asked about, let us say, cycle three of therapy, right? We did not have all of the right time points for all of the patients. But what we were able to do was to graph out some specific patient scenarios to illustrate how changes in ctDNA correlate with imaging response. I can talk a little bit about that. Dr. Rafeh Naqash: That was going to be my question. Did you see patients who had serial monitoring using the tumor informed ctDNA assay where the assay became positive a few months before the imaging? Did you have any of those kinds of observations? Dr. Julia Foldi: Yes, so I think this is where the field is going: are we able to use this technology to maybe detect progression before it becomes clinically apparent? Of course, there are lots of questions about: does that really matter? But it seems like, based on some of the patient scenarios that we present in the paper, that this testing can do that. So, we had a specific scenario, and this is illustrated in a figure in the paper, really showing the treatment as well as the changes in ctDNA, tumor markers, and also radiographic response. So, this particular patient was on first-line endocrine therapy and CDK4/6 inhibitor with palbociclib. Initially, she had a low-level detectable ctDNA. It became undetectable during treatment, and the patient had a couple of serial ctDNA assays that were negative, so undetectable. And then we started, after about seven months on this combination therapy, the ctDNA levels started rising. She actually had three serial ctDNA assays with increasing level of ctDNA before she even had any imaging tests. And then around the time that the ctDNA peaked, this patient had radiographic evidence of progression. There was also an NGS-based assay sent to look for specific mutations at that point. The patient was found to have an ESR1 mutation, which is very common in this patient population. She was switched to a novel oral SERD, elacestrant, and the ctDNA fell again to undetectable within the first couple months of being on elacestrant. And then a very similar thing happened: while she was on this second-line therapy, she had three serial negative ctDNA assays, and then the fourth one was positive. This was two months before the patient had a scan that showed progression again. Dr. Rafeh Naqash: And Julia, like you mentioned, this is a small sample size, limited number of patients, in this case, one patient case scenario, but provides insights into other important aspects around escalation or de-escalation of therapy where perhaps ctDNA could be used as an integral biomarker rather than an exploratory biomarker. What are some of your thoughts around that and how is the breast cancer space? I know like in GI and bladder cancer, there has been a significant uptrend in MRD assessments for therapeutic decision making. What is happening in the breast cancer space? Dr. Julia Foldi: So, super interesting. I think this is where a lot of our different fields are going. In the breast cancer space, so far, I have seen a lot of escalation attempts. It is not even necessarily in this particular setting where we are looking at dynamics of ctDNA, but in the breast cancer world, of course, we have a lot of data on resistance mutations. I mentioned ESR1 mutation in a particular patient in our study. ESR1 mutations are very common in patients with ER-positive breast cancer who are on long-term endocrine therapy, and ESR1 mutations confer resistance to aromatase inhibitors. So, that is an area that there has been a lot of interest in trying to detect ESR1 mutations earlier and switching therapy early. So, this was the basis of the SERENA-6 trial, which was presented last year at ASCO and created a lot of excitement. This was a trial where patients had non-tumor-informed NGS-based Guardant assay sent every three to six months while they were on first-line endocrine therapy with a CDK4/6 inhibitor. If they had an ESR1 mutation detected, they were randomized to either continue the same endocrine therapy or switch to an oral SERD. The trial showed that the population of patients who switched to the oral SERD did better in terms of progression-free survival than those who stayed on their original endocrine therapy. There are a lot of questions about how to use this in routine practice. Of course, it is not trivial to be sending a ctDNA assay every three to six months. The rate of detection of these mutations was relatively low in that study; again, the incidence increases in later lines of therapy. So, there are a lot of questions about whether we should be doing this in all of our first-line patients. The other question is, even the patients who stayed on their original endocrine therapy were able to stay on that for another nine months. So, there is this question of: are we switching patients too early to a new line of therapy by having this escalation approach? So, there are a lot of questions about this. As far as I know, at least in our practice, we are not using this approach just yet to escalate therapy. Time will tell how this all pans out. But I think what is even more interesting is the de-escalation question, and I think that is where tumor informed assays like Signatera and the data that our study generated can be applied. Actually, our plan is to generate some prospective data in the lobular breast cancer population, and I have an ongoing study to do that, to really be able to tease out the early ctDNA dynamics as patients first start on endocrine therapy. So, this is patients who are newly diagnosed, they are just starting on their first-line endocrine therapy, and measure, with sensitive assays, measure ctDNA dynamics in the first few months of therapy. In those patients who have a really robust response, that is where I think we can really think about de-escalation. In the patients whose ctDNA goes to undetectable after just a few weeks of therapy with just an endocrine agent, they might not even need a CDK4/6 inhibitor in their first-line treatment. So, that is an area where we are very interested in our group, and I know that other groups are looking at this too, to try to de-escalate therapy in patients who clear their ctDNA early on. Dr. Rafeh Naqash: Thank you so much. Well, lots of questions, but at the same time, progress comes through questions asked, and your project is one of those which is asking an interesting question in a rarer cancer and perhaps will lead to subsequent improvement in how we monitor these individuals and how we escalate or de-escalate therapy. Hopefully, we will get to see more of what you are working on in subsequent submissions to JCO Precision Oncology and perhaps talk more about it in a couple of years and see how the space and field is moving. Thanks again for sharing your insights. I do want to take one to two quick minutes talking about you as an investigator, Julia. If you could speak to your career pathway, your journey, the pathway to mentorship, the pathway to being a mentor, and how things have shaped for you in your personal professional growth. Dr. Julia Foldi: Sure, yeah, that is great. Thank you. So, I had a little bit of an unconventional path to clinical medicine. I actually thought I was going to be a basic scientist when I first started out. I got a PhD in Immunology right out of college and was studying not even anything cancer-related. I was studying macrophage signaling in inflammatory diseases, but I was in New York City. This was right around the time that the first checkpoint inhibitors were approved. Actually, some of my friends from my PhD program worked in Jim Allison's lab, who was the basic scientist responsible for ipilimumab. So, I got to kind of first-hand experience the excitement around bringing something from the lab into the clinic that actually changed really the course of oncology. And so, I got very excited about oncology and clinical medicine. So, I decided to kind of switch gears from there and I went back to medical school after finishing my PhD and got my MD at NYU. I knew I wanted to do oncology, so I did a research track residency and fellowship combined at Yale. I started working early on with the breast cancer team there. At the time, Lajos Pusztai was the head of translational research there at Yale, and I started working with him early in my residency and then through my fellowship. I worked on several trials with him, including a neoadjuvant checkpoint inhibitor trial in triple-negative breast cancer patients. During my last year in fellowship, I received a Conquer Cancer Young Investigator Award to study estrogen receptor heterogeneity using spatial transcriptomics in this subset of breast cancers that have intermediate estrogen receptor expression. From there, I joined the faculty at the University of Pittsburgh in 2022. So, I have been there about almost four years at this point. My interests really shifted slowly from triple-negative breast cancers towards ER-positive breast cancers. When I arrived in Pittsburgh, I started working very closely with some basic and translational researchers here who are very interested in estrogen signaling and mechanisms of resistance to endocrine therapy, and there is a large group here interested in lobular breast cancers. During my training, I was not super aware even that lobular breast cancer was a unique subtype of breast cancers, and that is, I think, changing a little bit. There is a lot more awareness in the breast cancer clinical and research community about ILC being a unique subtype, but it is not even really part of our training in fellowship, which we are trying to change. But I have become a lot more aware of this because of the research team here and through that, I have become really interested also on the clinical side. And so, we do have a Lobular Breast Cancer Research Center of Excellence here at the University of Pittsburgh and UPMC, and I am the leader on the clinical side. We have a really great team of basic and translational researchers looking at different aspects of lobular breast cancers, and some of the work that I am doing is related to this particular manuscript we discussed and the next steps, as I mentioned, a prospective study of early ctDNA dynamics in lobular patients. I also did some more clinical research work in collaboration with the NSABP looking at long-term outcomes of patients with lobular versus ductal breast cancers in some of their older trials. And so, that is, in a nutshell, a little bit about how I got here and how I became interested in ILC. Dr. Rafeh Naqash: Well, thank you for sharing those personal insights and personal journey. I am sure it will inspire other trainees, fellows, and perhaps junior faculty in trying to find their niche. The path, as you mentioned, is not always straight; it often tends to be convoluted. And then finding an area that you are interested in, taking things forward, and being persistent is often what matters. Dr. Julia Foldi: Thank you so much for having me. It was great. Dr. Rafeh Naqash: It was great chatting with you. And thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Join us for a compelling conversation with award-winning journalist and bestselling writer Wil Haygood (author of The Butler) as he discusses his latest book, The War Within a War: The Black Struggle in Vietnam and at Home (out February 10, 2026). Haygood reframes the Vietnam War not simply as a foreign conflict, but as a crucible in which the fight for civil rights followed Black Americans from the streets of the United States into the jungles of Southeast Asia. Drawing on deep research and vivid personal stories, he traces the lives of Black soldiers, airmen, doctors, nurses, journalists, and activists who fought simultaneously against enemy forces abroad and systemic racism at home. In The War Within a War, readers encounter figures both famous and obscure: from an Air Force pilot POW and a frontline surgeon to Marvin Gaye and Martin Luther King, Jr. The goal is to illuminate how this dual struggle reshaped both the war and the American conscience. This book goes beyond military history to explore how race and war intersected in ways that still echo in American life. Haygood's narrative brings urgency and humanity to a chapter of the Vietnam era that reshapes our understanding of service, sacrifice, and the unfinished fight for equality. Join us to hear from one of America's most insightful chroniclers of Black experience and national history, and to engage with the stories that still reverberate a half-century later. We're grateful to UPMC for Life  for sponsoring this event!

It's tax season… but not for our city's largest nonprofits, aka the Big Five. Mayor Corey O'Connor got some big wins with a pair of one-time donations from UPMC and PNC Bank's foundation last week, but what happens now? Our health care giants and major universities — UPMC, Highmark Health, the University of Pittsburgh, Carnegie Mellon University, and Duquesne University — collectively own about one-eighth of all the land in Pittsburgh. But because PA law considers them "purely public charities," they  don't have to pay property taxes like the rest of us. Host Megan Harris and executive producer Mallory Falk are talking about the rage people feel about that, how the courts created this mess, and various local efforts over the years to get these big nonprofits to "pay their fair share."  Have any special insight into negotiations with the nonprofits before the 2000s? Call or text our HOW DID THIS HAPPEN? HOTLINE at 412-212-8893. Learn more about the sponsor of this February 5th episode: P3R - Use code CITYCAST15 to save 15% off any event registration Become a member of City Cast Pittsburgh at membership.citycast.fm. Want more Pittsburgh news?  Sign up for our daily morning Hey Pittsburgh newsletter. We're on Instagram @CityCastPgh. Text or leave us a voicemail at 412-212-8893. Interested in advertising with City Cast? Find more info here. 

On this episode of the Project Purple Podcast, host Dino Verrelli sits down with Andy Lyons, a commercial photographer from the heart of the Midwest, Iowa, as he shares his deeply personal journey with familial pancreatic cancer. With a family history spanning three generations, affecting countless family members, including his grandmother, mother, and brother, Andy has long felt the shadow of this disease. Diagnosed in 2021 after over two decades of proactive screenings, including ultrasound endoscopies and genetic testing through research studies in Chicago and Pittsburgh, Andy was fortunate to catch his pancreatic cancer early. He reflects on the importance of vigilance and early detection, and how his experience demonstrates the power of knowledge, community, and persistence in managing a disease often considered a death sentence, even when it runs in your family. Andy shares the emotional and practical aspects of his journey: robotic surgery at UPMC, chemotherapy, the support of caregivers and his community, and the mental resilience that comes from maintaining humor, positivity, and hope. He emphasizes the importance of asking questions, connecting with other patients, and taking control of your health, summarized in the motto: “knowledge is power.” Through his story, Andy shows that pancreatic cancer is scary, but it's not invincible. He talks about the strength found in numbers, the hope that comes from proactive care, and even the symbolic meaning of a survivor tattoo and a healing blanket passed among friends as a gesture of solidarity. You can reach Andy at andyboylyons@gmail.com. Subscribe to the Project Purple Podcast for more stories from the pancreatic cancer community. To learn more or support Project Purple's mission of a world without pancreatic cancer, visit projectpurple.org.

Dr. Donald Yealy (Chief Medical officer UPMC) joins the show to talk about the weather and the impact on the numbers of people falling

Join the Veterans Breakfast Club for an open and wide-ranging virtual conversation about the military experience, past and present. We believe every veteran has a story to tell and wisdom to share. This event is a chance to listen, learn, and connect with others who understand the unique bonds and challenges of military service. If you have something on your mind—whether a personal memory, a question, or a topic you think deserves attention—we encourage you to bring it to the conversation. Veterans are also invited to email Shaun Hall at shaun@veteransbreakfastclub.org with any specific topics or issues they'd like to discuss. The Veterans Breakfast Club's mission is to create communities of listening around veterans and their stories, and our Open Conversations are one of the most dynamic ways we do that. These sessions are often wide-ranging, emotional, funny, and thought-provoking, providing a welcoming space where everyone's voice is valued. This event is free and open to all. To join the conversation live on Zoom, please use this link: https://us02web.zoom.us/j/6402618738. Or tune in on Facebook or YouTube at 7:00pm ET on February 2. Whether you have something to share or simply want to listen and learn, we welcome you to be part of the conversation! We're grateful to UPMC for Life  for sponsoring this event!

Some of our streets still haven't been cleared, nearly a week after the Pittsburgh region was hit with double digit snowfall. When can we expect some relief? And will UPMC's $10 million gift for emergency vehicles make things better? (Also, just how generous is this gift, really?) City Cast Pittsburgh host Megan Harris is joined by producer Sophia Lo and contributor Colin Williams to share the latest on snow removal. Plus, they discuss city and county efforts to restrict ICE activity, whether the new Steelers head coach counts as a win or loss for our city, and how you can help make a Pittsburgh-themed Lego set become a reality. Notes and references from today's show: UPMC gives $10M to city for plows, ambulances [Axios Pittsburgh] The challenges Pittsburgh Regional Transit faced before making rare decision to suspend service during snowstorm [Post-Gazette] Pittsburgh-area school districts are running out of snow days [KDKA] PODCAST: Mayor O'Connor on ICE, Affordability & AI [City Cast Pittsburgh] PODCAST: Can You Be Charged for Getting in ICE's Way? [City Cast Pittsburgh] Ways To Support Pittsburgh's Immigrant Communities [City Cast Pittsburgh] 'Pittsburgh is my world': Emotional Mike McCarthy introduced as new Steelers coach [Post-Gazette] Guild Journalists, Pittsburgh Community, Local Labor Comes Together to Launch PAPER [CWA] Architecture: Pittsburgh, Pennsylvania [Lego Ideas] Who Should Be On Pittsburgh's Walk of Fame? [City Cast Pittsburgh] Walk of Fame Nominations [Pittsburgh Walk of Fame] Learn more about the sponsors of this January 30th episode: Fulton Commons The Westmoreland Museum P3R Planned Parenthood of Western Pennsylvania Become a member of City Cast Pittsburgh at membership.citycast.fm. Want more Pittsburgh news? Sign up for our daily morning newsletter. We're also on Instagram @CityCastPgh! Interested in advertising with City Cast? Find more info here.

Pittsburgh Mayor held a news conference to announce a $10 million donation.

Join the Veterans Breakfast Club for a powerful livestream conversation with Michael Archer, U.S. Marine Corps veteran and author of A Patch of Ground: Khe Sanh, a firsthand account of one of the most intense and contested battles of the Vietnam War. Michael Archer is not writing as a distant historian or outside observer. He was a Marine at Khe Sanh. He lived on that patch of ground, endured the siege, and carried its weight with him long after leaving Vietnam. His book is rooted in direct experience—what it meant to be young, scared, exhausted, and determined, holding a remote combat base under constant artillery fire while the world debated whether Khe Sanh would become another Dien Bien Phu. A Patch of Ground is spare, unsentimental, and deeply personal. Archer writes about daily life under siege: patrols, bunkers, incoming rounds, boredom and terror existing side by side, and the bonds formed among Marines who depended on one another to survive. He also writes about memory—how Khe Sanh stayed with him, how veterans carry places like that inside them, and why telling the story matters decades later. In this conversation, we'll focus squarely on Archer's Marine Corps service and his experience at Khe Sanh: what he remembers, what surprised him looking back, and what gets lost when battles are reduced to maps, timelines, and strategic arguments. We'll talk about why Khe Sanh became such a symbol during the war, what it felt like on the ground to be part of that symbol, and how writing the book helped Archer make sense of an experience that never really ends. This is a conversation about combat, memory, and bearing witness—told by a Marine who was there, on that ground, and who has spent years finding the words to describe it. We're grateful to UPMC for Life  for sponsoring this event!

Marty opens the show speaking with Kristine (KDKA) and Dr. Donald Yealy (Chief Medical officer UPMC) about the weather and the impact it can have on your health

In this Veterans Breakfast Club livestream, we sit down with filmmaker Steven Grayhm to talk about Sheepdog, an independent feature film that takes a hard, honest look at combat trauma, recovery, and the long road home. Grayhm not only stars in the film, but also wrote, produced, and directed it—an unusual level of authorship that reflects how personal the project is. Sheepdog centers on Calvin Cole (Grayhm), a decorated U.S. Army combat veteran who is court-ordered into treatment and placed under the care of a VA trauma therapist-in-training (played by Madsen), who is juggling her clinical work with night shifts at a diner to pay for school. Calvin's fragile attempt to hold himself together is further tested when his father-in-law, a retired Vietnam veteran (Curtis Hall), appears at his door fresh out of prison. As Calvin's instinct to run from his past collapses, the film traces how accountability, compassion, and hard-earned trust can open a path toward healing. Shot on location in Western Massachusetts, Sheepdog aims to lift the veil on post-traumatic stress and the veteran suicide crisis, while also focusing on the often-overlooked idea of post-traumatic growth. Rather than offering easy answers, the film shows the physical and psychological consequences of trauma—and the slow, uneven work of recovery—through grounded performances and lived-in settings. Film critic Tony Toscana called it “one of the best films of the year.” We'll ask Grayhm about how Sheepdog came to be: years spent listening to veterans' stories, studying trauma and VA treatment models, and working closely with veterans and clinicians to get the details right. He'll reflect on why he felt compelled to tell this story himself, why authenticity matters more than spectacle, and what it takes to bring an independently made, veteran-centered film from script to screen. This livestream will explore the making of Sheepdog, the responsibilities of telling veterans' stories on film, and what cinema can—and cannot—do when it comes to understanding trauma, recovery, and the complicated work of coming home. We're grateful to UPMC for Life  for sponsoring this event!

Before he ever flew gunships in Vietnam or logged 900 combat hours over the Central Highlands, Gil Ferrey had already taken a remarkable detour into the frontlines of the Cold War. In the fall of 1961—just three weeks after construction began on the Berlin Wall—Gil, then a 20-year-old American student studying in East Berlin, attempted to help a young woman escape to the West. He and a friend, Victor Pankey, hid her in the trunk of their car and made a run for the border. They didn't make it. East German border guards arrested them at the crossing. What followed was four months in a state security prison, weeks of solitary confinement, a trial with a predetermined outcome, and an unexpected release reportedly granted as a personal “act of mercy” by Walter Ulbricht. The New York Times covered the case closely in 1962: two young Californians imprisoned for an act they considered morally right, even if East German law judged otherwise. When they emerged, shaggy-haired but unbroken, both said they'd been treated well. But the experience left its mark. Gil will tell the story of how a semester abroad in a sealed-off city became a collision with Communist state power and a firsthand look at the making of the Cold War's most visible boundary. But Ferrey's story doesn't end at Checkpoint Charlie. After returning home, finishing his studies at Claremont Men's College, and earning his commission, he went on to serve as an Army aviator. He trained at Fort Wolters and Fort Rucker, earned his wings in December 1964, and served first in Korea with the 7th Aviation Battalion, then stateside with the 11th Armored Cavalry Regiment. In Vietnam, Gill flew Hueys and Hiller 23G “Raven” scout helicopters, logging 900 combat hours. This is one of those rare veteran stories that opens a window not just onto a war, but onto an entire era. We're grateful to UPMC for Life  for sponsoring this event!

Join the Veterans Breakfast Club for an open and wide-ranging virtual conversation about the military experience, past and present. We believe every veteran has a story to tell and wisdom to share. This event is a chance to listen, learn, and connect with others who understand the unique bonds and challenges of military service. If you have something on your mind—whether a personal memory, a question, or a topic you think deserves attention—we encourage you to bring it to the conversation. Veterans are also invited to email Shaun Hall at shaun@veteransbreakfastclub.org with any specific topics or issues they'd like to discuss. The Veterans Breakfast Club's mission is to create communities of listening around veterans and their stories, and our Open Conversations are one of the most dynamic ways we do that. These sessions are often wide-ranging, emotional, funny, and thought-provoking, providing a welcoming space where everyone's voice is valued. This event is free and open to all. To join the conversation live on Zoom, please use this link: https://us02web.zoom.us/j/6402618738. Or tune in on Facebook or YouTube at 7:00pm ET on June 9. Whether you have something to share or simply want to listen and learn, we welcome you to be part of the conversation! We're grateful to UPMC for Life  for sponsoring this event!

Aerial photographs, weather observation and even food delivery are a few of the uses for drones. What about getting emergency medical equipment to rural areas where it’s needed, quickly? There’s now a public-private partnership aiming to use drones to do just that in central Pennsylvania. The U-S Department of Justice says it won’t require names of minors who received gender-affirming care at hospitals operated by UPMC. Patients' identities are embedded into their medical files. The holiday travel season is expected to set records. AAA estimates more than 122 million Americans will travel at least 50 miles from home between December 20th and January 1st. Pennsylvania Attorney General Dave Sunday is now serving in a leadership role among Eastern U-S attorneys general. More than 14-million dollars in grant funding is being awarded to community projects across Pennsylvania, by the state's Department of Community and Economic Development. The projects support communities in four areas: flood mitigation, recreational trails, improvements to sewage facilities and watersheds. More than 4.4 million dollars is being awarded to about 30 community projects in Dauphin County. If you're already a member of WITF's Sustaining Circle, you know how convenient it is to support programs like the Morning Agenda. By increasing your monthly gift, you can help WITF close the budget gap left by the loss of federal funding. Visit us online at witf.org/increase or become a new Sustaining Circle member at www.witf.org/givenow. Thank you.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

One week before the Tet Offensive of 1968, a small, unarmed Navy intelligence ship called the USS Pueblo was attacked and captured by North Korea. The seizure of the Pueblo became its own crisis running parallel to Tet, trapping 82 American sailors in a struggle for survival that lasted nearly a year. One of those sailors was 20-year-old Steven Woelk from Kansas. On our upcoming VBC livestream, Steven will join us to share his remarkable firsthand story, now told in full in his soon-to-be-released memoir, Pig Fat Soup: Surviving My Pueblo Prisoner of War Journey. When cannon rounds started ripping into the lightly armed spy ship, Woelk was below decks with three shipmates, frantically trying to burn classified material before it could be captured. The smoke gave them away. A North Korean round tore through their space, killing Woelk's friend and leaving Woelk himself gravely wounded. Because of those wounds, he became the last sailor to leave the Pueblo. Carried off the ship after Commander Lloyd Bucher surrendered to prevent further slaughter, Woelk then went ten full days without medical treatment. When surgery finally came, it was brutal. Shrapnel, bone fragments, and his testicles were removed without anesthesia. He still has no idea how he survived without infection. Woelk spent forty-four days in a North Korean hospital, which spared him some of the savage beatings his crewmates endured. But nothing shielded him from “hell week,” the torture that followed once the captors discovered the crew's defiant middle-finger gesture wasn't, in fact, a friendly Hawaiian greeting. “You pray you're strong enough to resist,” he later said, “but you never know until you face that reality.” There were long stretches of boredom, hunger, and fear, punctuated by sudden terror, never knowing whether the next moment would bring a beating, execution, or, by some miracle, release. Release finally came two days before Christmas 1968. For his wounds and captivity, Woelk received two Purple Hearts and the POW Medal. The Pueblo remains the only U.S. Navy vessel still held by a foreign nation, displayed by North Korea as a trophy and propaganda exhibit. Steven Woelk has spent much of his life ensuring that the Pueblo is not forgotten. His memoir, Pig Fat Soup, offers the most detailed and candid account he's ever shared—one that moves from the chaos of the attack to the freezing bunkrooms of the “Barn,” the POW camp where the crew endured nearly a year of captivity. We're grateful to UPMC for Life  for sponsoring this event!

Marty Speaks with Maribeth McLaughlin ( Chief Nurse Executive UPMC) about a graduating class and the needed influx of nurses

The recently passed Pennsylvania state budget includes more money for tuberculosis prevention efforts in the Commonwealth. Federal data show cases of TB steadily rising nationally after nearly three decades of decline. The University of Pittsburgh Medical Center is establishing a rural residency program in an effort to bolster the rural doctor workforce. Here’s how it works: Residents start at UPMC Williamsport before transferring to either UPMC Wellsboro or UPMC Cole in Coudersport. Both locations are in Pennsylvania’s northern tier known as the Pennsylvania Wilds region. In Cumberland County, an 80-year-old woman was found dead after a house fire early Sunday morning, according to the Cumberland County Coroner's Office. State officials discovered a month's worth of mail wasn't sent by a government-contracted mail house over the past month. The backlog of mail totals 3.4 million letters, including notices of SNAP eligibility and health benefit information, as well as driver’s license and vehicle registration renewal invitations from PennDOT. Pennsylvania lawmakers could end the year with the lowest number of new laws in at least a decade. That's due to split government, heightened partisanship, and the concentration of power in the hands of legislative leaders, according to reporting by our partners at Spotlight PA. Sunday marked the beginning of Hanukkah. The city of Lancaster and the Jewish Community Alliance of Lancaster hosted a menorah lighting in Penn Square. Did you know that if every sustaining circle member gives as little as $12 more a month, we'd close the gap caused by federal funding cuts? Increase your gift at https://witf.org/increase or become a new Sustaining Circle member at www.witf.org/givenow.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

Edward Ford and Alan Chiasson came to Afghanistan with long résumés in uniform and out. Ford was a Force Recon Marine with combat tours in the Gulf War, Somalia, Iraq, and Afghanistan before moving into high-end security contracting. Chiasson was a Navy Hospital Corpsman and Texas paramedic who'd spent years providing high-risk medical support on PSD and convoy details in Iraq and Afghanistan. When the private security firm SOC (Special Operations Consulting) expanded its mobile operations in Afghanistan, both men ended up on armored Ford F-550 gun trucks running some of the most dangerous roads in the country. At first, their teams hauled critical supplies—ammo, fuel, food, equipment—to isolated Special Forces sites and small outposts the regular military couldn't cover. Then SOC picked up the Department of Defense contract to move something that sounded almost ordinary: the mail. Ford, Chiasson, and their teammates suddenly became the unofficial “Pony Express” of Afghanistan, hauling letters and care packages from Kabul and Bagram along the notorious Ring Road to places like Ghazni, Sharana, Orgun-E, and tiny dirt compounds with nothing but Hesco walls and a few tents. Troops took the mail for granted; few ever thought about the chain of convoys and gun trucks that got a letter from a stateside mailbox to a cot in Kandahar. Postcards Through Hell tells that story from the inside. The “Pony Express” ran four teams in a three-on, one-off rotation so three could be on the road at any time. One team took the long hauls, another ran the shorter Kabul ring route while standing QRF, and a third trained, refit, and got ready to swap in. A “good” day might mean an 18-hour, thousand-kilometer push with no major incidents—what they jokingly called the “Thousand Kilometer Club.” Most days weren't like that. They drove flat-bottom F-550s with level-seven armor and twin turrets, strong against small arms but vulnerable to anything placed directly underneath. Once the Taliban figured out that weakness, a well-buried mine or IED under the chassis could flip a truck or tear it in half. The book is anchored in specific days and events. Ford saved incident reports, op orders, and run paperwork; Chiasson kept a journal. Together they rebuilt a timeline that lets them write, “On April 30 we were here; on May 1 this happened,” instead of “sometime that spring.” Around those convoy stories they layer the wider war: the Camp Chapman suicide bombing; Special Forces “kill teams” at outposts like Ramrod; Italian forces paying the Taliban not to attack them, which meant somebody else—often the Pony Express—became the target. They were there when other contractor convoys got hit, when friends died in F-550s blown apart by stacked anti-tank mines, and when gun trucks limped back into Kabul with wounded men inside and burned-out hulks left behind on the road. Their daily life was built around a simple idea: keep your brothers alive. When they weren't running missions, they were on QRF. When they weren't on QRF, they were working out. When they weren't working out, they were training. They ate together, lived on top of each other in cramped villas and compounds, and used the long Afghan “fighting season”—April through October—to sort out who really belonged there. The easy-sounding mail run weeded people out fast. Some new hires lasted one fighting season, some one mission, some one week. Others stayed for years, until they hit what Ford calls “the wall”—that private moment when you look at a body on a slab, or feel age and accumulated blast damage catching up with you, and decide it's time to go home. Postcards Through Hell doesn't ignore the business side of contracting. Ford and Chiasson talk frankly about companies weighing the cost of vehicle upgrades against death-benefit payouts, replacing seasoned expatriate drivers with cheaper local nationals, and relying on Afghan “expediters” whose loyalties sometimes ran in more than one direction.  The story doesn't end when the convoys stop. The contract itself ran, under different companies, into 2016, and Ford and Chiasson had to cut whole chapters from the book because of classified work and units involved.  At heart, Postcards Through Hell is a book about a very unglamorous, absolutely vital piece of America's longest war.  We're grateful to UPMC for Life  for sponsoring this event!

Today's guest is Dr. Kathryn Torok, a pediatric rheumatologist at the University of Pittsburgh and UPMC Children's Hospital of Pittsburgh, where she directs the Pediatric Craniofacial Scleroderma Clinic. Scleroderma in children is rare, about five in 100,000 develop localized disease, and only about one in a million develop systemic disease. It's crucial to treat to target as early as possible. I learned so much from Dr. Torok about how scleroderma affects children and the best approaches to care.

In this episode, Chris Carmody, SVP and CTO of UPMC, discusses the health system's journey toward a single Epic instance, including the technological and organizational hurdles of wave one of the UPMC Bridges project. He shares lessons learned, how UPMC approaches integrating newly acquired sites, and what sets their large scale consolidation apart as they prepare for Wave Two.

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Happy Thursday everyone! Every week we ask the public if they have a topic in mind, and this week you delivered! Amy Gibbons, a Gaelic football player and coach, reached out to us about her 3rd ACL rupture. She is a major advocate for research into why ACL injuries are so prevalent in women's sports, and what can be done to mitigate it. We spoke to her about her own journey and recovery, as well as rugby player Aoibheann Reilly, Kildare football lead s&c Dr Neil Welch, and UPMC consultant orthopaedic surgeon Professor Brian Devitt for this special episode.Have a topic or thought in mind? Send us a DM on @offtheball on all our social platforms or send us a WhatsApp at 087 9 180 180!

Recorded live at Abridge's Executive Summit at the Becker's 10th Annual Health IT + Digital Health + RCM Conference, this panel features Chris Carmody of UPMC, Misti Foust-Cofield of Reid Health, and Justin Brueck of Endeavor discussing how AI and ambient technology are reducing burnout, improving clinician satisfaction, and reshaping the future of patient care.This episode is sponsored by Abridge.

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Chris Horvat, Senior Director of Clinical Informatics at UPMC, discussing the leveraging of generative AI and machine learning in healthcare. He also offers advice for emerging leaders on navigating the evolving digital health landscape.

This episode features Dr. Richard Celko, Chief Dental Officer at UPMC Health Plan who discusses challenges with access to dental care in rural areas, strategies for addressing community needs, and insights on current events shaping the dental industry.

This episode recorded live at the 10th Annual Health IT + Digital Health + RCM Annual Meeting features Deepan Kamaraj, Director, Analytics & Informatics, UPMC Enterprises. Kamaraj shares how UPMC is testing and deploying AI responsibly through data governance, closed-container evaluations, and cross-functional collaboration, while offering guidance for leaders balancing innovation, regulation, and operational efficiency.